Close

Search

Subscribe
Browse Tag

Phase 3

2 Articles
Illustration of immune cells targeting a bladder tumor, with a bank and coins representing Forlong Biotech’s financing.

Forlong Biotech’s Pre-B Financing Reaches Nearly RMB 200 Million as It Prepares FL115 for Phase 3 Bladder Cancer Trial

By Xiaoxin Du
No Comments on Forlong Biotech’s Pre-B Financing Reaches Nearly RMB 200 Million as It Prepares FL115 for Phase 3 Bladder Cancer Trial
2 Min Read

Forlong Biotech has completed the second close of its Pre-B financing, bringing the round’s total to nearly RMB 200 million. Fosun Health Capital’s new drug fund led the latest close, which raised more than RMB 100 million, according to Chinese financing…

Illustration of lungs with a tumor and a magnified antibody-drug conjugate labeled B7-H3 ADC binding to a cancer cell.

GSK and Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial

By Henry Tseng
No Comments on GSK and Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial
5 Min Read

GSK and Hansoh Pharma’s B7-H3-directed antibody-drug conjugate risvutatug rezetecan delivered a striking survival benefit in relapsed small-cell lung cancer, potentially setting a new benchmark for a disease in which treatment progress has historically…